Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Marimastat. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP1 known ✓ | P03956 | 9/20 | 1.00 |
| ▸ | MMP2 known ✓ | P08253 | 8/20 | 1.00 |
| ▸ | MMP3 known ✓ | P08254 | 6/20 | 1.00 |
| ▸ | MMP9 known ✓ | P14780 | 5/20 | 1.00 |
| ▸ | MMP7 known ✓ | P09237 | 3/20 | 1.00 |
| ▸ | MMP12 known ✓ | P39900 | 1/20 | 1.00 |
| ▸ | ADAM17 | P78536 | 13/20 | 1.00 |
| ▸ | MMP8 | P22894 | 6/20 | 1.00 |
| ▸ | MMP13 | P45452 | 3/20 | 1.00 |
| ▸ | TNF | P01375 | 2/20 | 1.00 |
| ▸ | MMP20 | O60882 | 1/20 | 1.00 |
| ▸ | ADAMTS4 | O75173 | 1/20 | 1.00 |
| ▸ | MMP10 | P09238 | 1/20 | 1.00 |
| ▸ | MMP14 | P50281 | 1/20 | 1.00 |
| ▸ | MMP15 | P51511 | 1/20 | 1.00 |
| ▸ | MMP16 | P51512 | 1/20 | 1.00 |
| ▸ | MMP25 | Q9NPA2 | 1/20 | 1.00 |
| ▸ | MMP26 | Q9NRE1 | 1/20 | 1.00 |
| ▸ | ADAMTS5 | Q9UNA0 | 1/20 | 1.00 |
| ▸ | MMP24 | Q9Y5R2 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Marimastat SCHEMBL31231856 | 1.00 | ADAM17 (1.00) | ADAM17MMP1MMP2MMP3MMP8 | |
| Marimastat SCHEMBL8189167 | 1.00 | ADAM17 (1.00) | ADAM17MMP1MMP2MMP3MMP8 | |
| Marimastat SCHEMBL1821430 | 1.00 | ADAM17 (1.00) | ADAM17MMP1MMP2MMP3MMP8 | |
| Marimastat SCHEMBL13253251 | 1.00 | ADAM17 (1.00) | ADAM17MMP1MMP2MMP3MMP8 | |
| Marimastat SCHEMBL34033 | 1.00 | ADAM17 (1.00) | ADAM17MMP1MMP2MMP3MMP8 | |
| Marimastat SCHEMBL8193003 | 1.00 | ADAM17 (1.00) | ADAM17MMP1MMP2MMP3MMP8 | |
| Marimastat SCHEMBL13575773 | 1.00 | ADAM17 (1.00) | ADAM17MMP1MMP2MMP3MMP8 | |
| Marimastat SCHEMBL134999 | 1.00 | ADAM17 (1.00) | ADAM17MMP1MMP2MMP3MMP8 | |
| Marimastat SCHEMBL20793036 | 1.00 | ADAM17 (1.00) | ADAM17MMP1MMP2MMP3MMP8 | |
| Marimastat SCHEMBL7931107 | 0.99 | ADAM17 (0.97) | ADAM17MMP1MMP2MMP3MMP8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200390912-A1 | EVALUATION OF PRESENCE OF AND VULNERABILITY TO ATRIAL FIBRILLATION AND OTHER INDICATIONS USING MATRIX METALLOPROTEINASE-BASED IMAGING | LANTHEUS MEDICAL IMAGING, INC. (US) | 2020-12-17 | — | — | US | disclosed |
| US-20200087648-A1 | PARKIN LIGASE ACTIVATION METHODS AND COMPOSITIONS | NYSNOBIO IRELAND DAC (IE) | 2020-03-19 | — | — | US | disclosed |
| US-10155936-B2 | Parkin ligase activation methods and compositions | An2H Discovery Limited (IE) | 2018-12-18 | — | — | US | disclosed |
| US-20180177901-A1 | EVALUATION OF PRESENCE OF AND VULNERABILITY TO ATRIAL FIBRILLATION AND OTHER INDICATIONS USING MATRIX METALLOPROTEINASE-BASED IMAGING | LANTHEUS MEDICAL IMAGING, INC. (US) | 2018-06-28 | — | — | US | disclosed |
| US-20160160205-A1 | PARKIN LIGASE ACTIVATION METHODS AND COMPOSITIONS | An2H Discovery Limited (IE) | 2016-06-09 | — | — | US | disclosed |
| US-20160160205-A1 | PARKIN LIGASE ACTIVATION METHODS AND COMPOSITIONS | An2H Discovery Limited (IE) | 2016-06-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10155936-B2 | Parkin ligase activation methods and compositions | PINK1, XIAP, STUB1 | MMP1 3207/4885MMP2 2913/4885MMP3 3156/4885 |
| US-20180177901-A1 | EVALUATION OF PRESENCE OF AND VULNERABILITY TO ATRIAL FIBRILLATION AND OTHER INDICATIONS USING MATRIX METALLOPROTEINASE-BASED IMAGING | MMP3, MMP1, TIMP3 | MMP1 2/4885MMP2 19/4885MMP3 1/4885 |
| US-20200087648-A1 | PARKIN LIGASE ACTIVATION METHODS AND COMPOSITIONS | PINK1, XIAP, STUB1 | MMP1 3207/4885MMP2 2913/4885MMP3 3156/4885 |
| US-20160160205-A1 | PARKIN LIGASE ACTIVATION METHODS AND COMPOSITIONS | PINK1, XIAP, STUB1 | MMP1 3207/4885MMP2 2913/4885MMP3 3156/4885 |
| US-20200390912-A1 | EVALUATION OF PRESENCE OF AND VULNERABILITY TO ATRIAL FIBRILLATION AND OTHER INDICATIONS USING MATRIX METALLOPROTEINASE-BASED IMAGING | MMP3, MMP1, TIMP3 | MMP1 2/4885MMP2 19/4885MMP3 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.